I wouldn't read too much into this yet. The funding was there and the trials would have started in July according to the information we received earlier. This means that they would be 4-8 weeks into their clinical protocol and the first evaluation point isn't until the 12 week mark.
The only reason I can come up with is that something went wrong in the beginning of the trials and that they're either postponed indefinitely or that there was a major safety concern discovered early on and that they had to shut down and re-evaluate. Either way I don't understand the people calling it a scam; They had absolutely nothing to gain and a lot to lose by drawing attention to themselves and then failing in the eyes of both their investors and the public. They most certainly believed in their product and none of the possible reasons I can see for this implies a lack of potential but rather unforeseen circumstances.
There's also the chance that something is merely being updated/edited. It wouldn't be the first time something changed on an internet page and made everybody throw a hissy fit.
Either way I won't react to it until there's official word from Histogen.
The only reason I can come up with is that something went wrong in the beginning of the trials and that they're either postponed indefinitely or that there was a major safety concern discovered early on and that they had to shut down and re-evaluate. Either way I don't understand the people calling it a scam; They had absolutely nothing to gain and a lot to lose by drawing attention to themselves and then failing in the eyes of both their investors and the public. They most certainly believed in their product and none of the possible reasons I can see for this implies a lack of potential but rather unforeseen circumstances.
There's also the chance that something is merely being updated/edited. It wouldn't be the first time something changed on an internet page and made everybody throw a hissy fit.
Either way I won't react to it until there's official word from Histogen.
Comment